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LESS	  INTENSIVE	  THERAPY	  FOR	  OLDER	  AML	  PATIENTS.	  W.	  Thomas	  Clarke,	  Peter	  
W.	  Marks,	  and	  Nikolai	  A.	  Podoltsev.	  Section	  of	  Hematology,	  Department	  of	  Internal	  
Medicine,	  Yale	  University	  School	  of	  Medicine,	  New	  Haven,	  CT.	  
Specific	  aims:	  This	  single-­‐center,	  retrospective	  study	  compared	  overall	  survival	  
and	  hospitalization	  in	  older	  patients	  with	  acute	  myeloid	  leukemia	  (AML)	  receiving	  
first-­‐line	  treatment	  with	  standard	  induction	  chemotherapy	  and	  decitabine	  therapy.	  
Methods:	  Between	  January	  2000	  and	  December	  2009,	  36	  patients	  at	  Yale-­‐New	  
Haven	  Hospital	  age	  65	  years	  and	  older	  with	  newly	  diagnosed	  AML	  received	  
standard	  induction	  chemotherapy	  (n=11),	  decitabine	  therapy	  (n=11),	  or	  supportive	  
care	  only	  (n=14).	  Data	  obtained	  included	  baseline	  characteristics,	  achievement	  of	  
remission,	  overall	  survival,	  inpatient	  and	  outpatient	  visits,	  and	  early	  death.	  
Results:	  When	  compared	  to	  standard	  induction	  chemotherapy,	  decitabine	  patients	  
were	  significantly	  older	  (77	  vs	  69	  years,	  P	  =	  .020)	  yet	  had	  a	  favorable	  but	  
nonsignificant	  trend	  for	  increased	  overall	  survival	  (9	  vs	  7	  months,	  P	  =	  .192)	  and	  
spent	  significantly	  fewer	  days	  in	  the	  hospital	  (30	  vs	  41	  days,	  P	  =	  	  .047).	  Supportive	  
care	  patients	  were	  older	  (84.5	  years)	  and	  had	  a	  median	  survival	  of	  only	  0.6	  months.	  
Conclusions:	  Compared	  to	  standard	  induction	  chemotherapy,	  decitabine	  as	  first-­‐
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Leukemia	  is	  a	  cancer	  of	  the	  blood	  and	  bone	  marrow.	  Classification	  is	  first	  made	  into	  
acute	  or	  chronic	  forms	  of	  the	  disease.	  Acute	  leukemias	  are	  characterized	  by	  a	  rapid	  
increase	  in	  the	  number	  of	  neoplastic,	  immature	  bone	  marrow	  cells.	  Chronic	  
leukemias	  are	  characterized	  by	  a	  slower	  accumulation	  of	  relatively	  more	  mature	  
neoplastic	  blood	  cells.	  Further	  classification	  is	  made	  based	  on	  the	  affected	  cell	  type.	  
In	  lymphocytic	  leukemias,	  the	  cancer	  arises	  in	  cells	  destined	  to	  become	  
lymphocytes.	  In	  myelogenous	  leukemias,	  the	  cancer	  occurs	  in	  precursor	  cells	  
destined	  to	  become	  red	  blood	  cells,	  platelets,	  neutrophils,	  monocytes,	  and	  some	  
other	  types	  of	  white	  cells.	  	  
	  
In	  acute	  myeloid	  leukemia	  (AML),	  non-­‐functional	  neoplastic	  cells	  replace	  the	  normal	  
blood	  cell	  precursors	  in	  the	  bone	  marrow.	  	  A	  deficiency	  of	  white	  blood	  cells	  makes	  
patients	  susceptible	  to	  infection.	  Anemia,	  a	  reduction	  in	  red	  blood	  cells,	  causes	  
fatigue.	  Thrombocytopenia,	  an	  abnormally	  low	  platelet	  count,	  results	  in	  bleeding	  or	  
easy	  bruising	  (1).	  Other	  related	  symptoms	  include	  fevers	  with	  night	  sweats,	  loss	  of	  
appetite,	  enlarged	  liver	  or	  spleen,	  and	  bone	  or	  joint	  pain.	  Leukemic	  cells	  may	  
infiltrate	  skin	  and	  other	  organs	  and	  cause	  hyperviscosity	  and	  disseminated	  
intravascular	  coagulation	  (DIC)	  (2).	  	  
	  
Epidemiology	  
In	  2012,	  it	  is	  estimated	  that	  13,780	  people	  in	  the	  United	  States	  will	  be	  diagnosed	  
with	  AML.	  In	  the	  same	  year,	  10,200	  people	  will	  die	  of	  the	  disease.	  The	  age-­‐adjusted	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incidence	  and	  death	  rates	  were	  3.6	  and	  2.8,	  respectively,	  per	  100,000	  men	  and	  
women	  per	  year.	  The	  median	  age	  at	  diagnosis	  is	  66	  years	  and	  the	  median	  age	  at	  
death	  72	  years	  (3).	  AML	  has	  a	  peak	  incidence	  in	  the	  80-­‐84	  year	  old	  age	  range	  (4).	  
Men	  are	  more	  likely	  than	  women	  to	  be	  diagnosed	  with	  (4.3	  versus	  3.0	  per	  100,000)	  
and	  die	  from	  (3.7	  versus	  2.2	  per	  100,000)	  AML.	  By	  race,	  whites	  have	  the	  highest	  
incidence	  rate	  and	  death	  rate.	  The	  overall	  five-­‐year	  survival	  rate	  between	  2002	  and	  
2008,	  the	  most	  recent	  available	  data,	  was	  23.4%	  (3).	  	  
	  
Classification	  
AML	  is	  a	  heterogeneous	  disorder	  that	  is	  classified	  by	  two	  systems,	  the	  newer	  World	  
Health	  Organization	  (WHO)	  system	  and	  the	  older	  French-­‐American-­‐British	  (FAB)	  
system.	  The	  WHO	  classification	  is	  based	  on	  common	  cytogenetic	  and	  molecular	  
genetic	  abnormalities	  and	  is	  important	  for	  both	  treatment	  and	  prognosis.	  The	  WHO	  
subtypes	  of	  AML	  include:	  AML	  with	  recurrent	  genetic	  abnormalities;	  AML	  with	  
myelodysplasia-­‐related	  changes;	  therapy	  related	  myeloid	  neoplasms;	  AML,	  not	  
otherwise	  specified	  (NOS);	  myeloid	  sarcoma;	  myeloid	  proliferations	  related	  to	  
Down	  syndrome;	  blastic	  plasmacytoid	  dendritic	  cell	  neoplasm;	  and	  acute	  leukemias	  
of	  ambiguous	  lineage	  (5,6).	  The	  FAB	  system,	  initially	  proposed	  in	  1976,	  is	  rarely	  
used	  today	  and	  relies	  on	  older	  morphologic,	  cytochemical,	  and	  immunophenotypic	  
features	  of	  neoplastic	  cells	  (7).	  
	  
The	  first	  WHO	  subgroup,	  AML	  with	  recurrent	  genetic	  abnormalities,	  includes	  
patients	  with	  one	  of	  many	  well-­‐defined	  genetic	  abnormalities	  of	  prognostic	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significance.	  Nearly	  30%	  of	  AML	  patients	  are	  included	  in	  this	  group.	  Some	  examples	  
of	  these	  genetic	  abnormalities	  include:	  t(15;17);	  t(8;21);	  and	  inv(16)	  (5).	  AML	  
associated	  with	  these	  abnormalities	  are	  notable	  for	  having	  a	  favorable	  response	  to	  
treatment	  (8).	  	  
	  
The	  second	  WHO	  subgroup,	  AML	  with	  myelodysplasia-­‐related	  changes,	  includes	  
patients	  with	  a	  documented	  history	  of	  myelodysplastic	  syndrome	  (MDS)	  or	  a	  
myeloproliferative	  neoplasm	  who	  evolve	  to	  AML	  with	  a	  marrow	  or	  blood	  blast	  
count	  of	  greater	  than	  20%.	  	  The	  subgroup	  also	  includes	  patients	  without	  such	  a	  
history	  that	  meet	  one	  of	  two	  specific	  criteria.	  In	  the	  first	  criteria,	  50%	  or	  more	  of	  the	  
cells	  in	  two	  or	  more	  myeloid	  lineages	  are	  dysplastic	  (6).	  In	  the	  second	  criteria,	  the	  
neoplastic	  cells	  must	  demonstrate	  specific	  MDS-­‐related	  cytogenetic	  abnormalities	  
(9).	  The	  incidence	  of	  AML	  with	  myelodysplasia-­‐related	  changes	  is	  higher	  in	  elderly	  
populations	  (10)	  and	  has	  been	  independently	  shown	  to	  be	  associated	  with	  lower	  
rates	  of	  complete	  remission	  (11).	  
	  
Therapy-­‐related	  myeloid	  neoplasms,	  the	  third	  subgroup,	  includes	  patients	  with	  a	  
history	  of	  chemotherapy	  and/or	  radiation	  who	  subsequently	  develop	  AML	  or	  MDS.	  
Topoisomerase	  II	  inhibitor-­‐related	  AML	  has	  a	  short	  latency	  period,	  ranging	  from	  six	  
months	  to	  five	  years,	  characteristic	  translocations,	  and	  poor	  overall	  survival	  (12).	  
Alkylating	  agent/radiation-­‐related	  AML	  has	  a	  longer	  latency	  period	  ranging	  from	  
four	  to	  seven	  years	  and	  is	  notable	  for	  a	  high	  incidence	  of	  abnormalities	  in	  
chromosomes	  5	  and	  7	  (13).	  However,	  many	  patients	  have	  received	  treatment	  with	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both	  topoisomerase	  II	  targeting	  drugs	  and	  alkylating	  agents,	  so	  dividing	  this	  
subgroup	  by	  previous	  therapy	  is	  often	  not	  possible	  (6).	  
	  
The	  remaining	  WHO	  subgroups	  provide	  a	  specific	  framework	  for	  patients	  that	  do	  
not	  fit	  into	  one	  of	  the	  three	  previously	  mentioned	  most	  common	  subgroups	  (5).	  	  
	  
Myelodysplastic	  syndrome	  and	  myeloproliferative	  neoplasm	  
MDS	  and	  myeloproliferative	  neoplasm	  are	  also	  clonal	  bone	  marrow	  disorders	  of	  the	  
myeloid	  cell	  line.	  While	  distinct	  entities	  from	  AML,	  both	  MDS	  and	  MPN	  have	  the	  
potential	  to	  transform	  into	  AML;	  one-­‐third	  of	  MDS	  cases	  transforms	  to	  AML	  (14).	  
The	  WHO	  and	  FAB	  classifications	  have	  different	  criteria	  for	  the	  diagnosis	  of	  AML	  
and	  MDS.	  The	  WHO	  classification	  for	  AML	  requires	  leukemic	  myeloblasts	  constitute	  
more	  than	  20%	  of	  the	  blood	  or	  bone	  marrow	  cells	  (15)	  while	  the	  older	  FAB	  
classification	  requires	  at	  least	  30%	  (7).	  There	  exists	  a	  strong	  correlation	  between	  
age	  and	  MDS	  diagnoses;	  patients	  over	  age	  70	  have	  an	  incidence	  rate	  of	  MDS	  nearly	  
three	  times	  greater	  than	  of	  AML	  (10).	  	  
	  
Myeloproliferative	  neoplasms	  are	  a	  group	  of	  hematologic	  neoplasms	  separated	  into	  
two	  distinct	  groups	  based	  on	  the	  presence	  or	  absence	  of	  the	  Philadelphia	  
chromosome.	  Chronic	  myelogenous	  leukemia	  (CML)	  carries	  the	  t(9;22)	  BCR-­‐ABL	  
translocation	  Philadelphia	  chromosome.	  Philadelphia	  chromosome	  negative	  MPNs	  
include	  primary	  myelofibrosis,	  polycythemia	  vera,	  and	  essential	  thrombocytopenia.	  
With	  current	  treatments,	  life	  expectancy	  is	  near	  normal	  in	  the	  majority	  of	  patients	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with	  CML,	  polycythemia	  vera,	  and	  essential	  thrombocytopenia	  (16).	  Current	  




There	  are	  many	  factors	  that	  contribute	  to	  prognosis	  and	  treatment	  decisions	  in	  
patients	  with	  newly	  diagnosed	  AML.	  These	  include	  age,	  performance	  status,	  WHO	  
classification,	  karyotype,	  and	  molecular	  studies.	  	  
	  
Age	  
Increasing	  age	  is	  a	  poor	  prognostic	  factor	  in	  AML	  across	  all	  age	  groups.	  In	  a	  study	  of	  
1181	  patients	  under	  30	  years,	  5-­‐year	  event	  free	  survival	  was	  54%	  in	  children	  less	  
than	  13	  years,	  46%	  in	  adolescents	  between	  13	  and	  18	  years,	  and	  28%	  in	  young	  
adults	  between	  18	  and	  30	  years	  (18).	  In	  a	  Swedish	  study	  of	  2767	  adults	  with	  AML,	  
older	  patients	  fared	  worse	  in	  every	  measurable	  category.	  They	  were	  more	  likely	  to	  
have	  a	  poor	  performance	  status	  and	  less	  likely	  to	  be	  fit	  for	  intensive	  chemotherapy.	  
They	  had	  a	  higher	  rate	  of	  early	  death	  (defined	  as	  within	  30	  days	  of	  initial	  remission	  
induction):	  4%	  in	  patients	  less	  than	  50	  years,	  14%	  in	  patients	  65	  through	  69	  years	  
old,	  and	  40%	  in	  patients	  over	  85	  years.	  Older	  patients	  had	  lower	  median	  overall	  
survival:	  1119	  days	  in	  patients	  16	  through	  55	  years	  compared	  with	  80	  days	  in	  
patients	  76	  through	  89	  years	  old	  (4).	  In	  another	  large	  study	  of	  adults,	  patients	  
younger	  than	  56	  years	  old	  achieved	  complete	  response	  in	  64%	  of	  cases	  compared	  to	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33%	  of	  patients	  older	  than	  75	  years.	  Median	  disease-­‐free	  survival	  was	  nearly	  2.5	  
times	  greater	  in	  patients	  younger	  than	  56	  years	  than	  those	  older	  than	  75	  years	  (19).	  
	  
Not	  surprisingly,	  performance	  status	  declines	  with	  age.	  Excellent	  performance	  
status	  was	  found	  in	  a	  lower	  percentage	  of	  patients	  as	  age	  increased,	  from	  35%	  in	  
those	  less	  than	  56	  years	  old	  to	  18%	  in	  those	  older	  than	  75	  years	  (19).	  Older	  patients	  
are	  more	  likely	  to	  have	  chronic	  diseases	  including	  diabetes	  and	  renal,	  cardiac,	  and	  
hepatic	  disorders.	  These	  chronic	  diseases	  make	  patients	  less	  able	  to	  tolerate	  
chemotherapy.	  Furthermore,	  older	  patients	  have	  reduced	  bone	  marrow	  
regenerative	  capacity	  following	  chemotherapy	  (20).	  However,	  studies	  show	  that	  age	  
and	  performance	  status	  are	  each	  independent	  risk	  factors	  in	  AML.	  In	  one	  study,	  
patients	  less	  than	  56	  years	  of	  age	  and	  over	  75	  years	  of	  age	  with	  the	  same	  moderate	  
performance	  status	  were	  compared.	  In	  the	  younger	  group,	  2%	  suffered	  an	  early	  
death.	  In	  the	  older	  group,	  64%	  had	  an	  early	  death	  (19).	  	  
	  
Cytogenetics	  
It	  is	  well	  established	  that	  diagnostic	  cytogenetics	  is	  one	  of	  the	  most	  powerful	  
prognostic	  indicators	  in	  AML	  (21,22).	  The	  Cancer	  and	  Leukemia	  Group	  B	  (CALGB)	  
devised	  risk	  groups	  to	  predict	  success	  of	  induction	  chemotherapy	  and	  overall	  
survival.	  Karyotypes	  including	  t(8;21),	  t(15,17),	  t(16;16),	  and	  inv(16)	  are	  known	  to	  
confer	  a	  significantly	  better	  prognosis	  than	  other	  karyotypes,	  and	  patients	  with	  
these	  karyotypes	  are	  in	  the	  CALGB	  “favorable”	  cytogenetic	  risk	  group	  (22,23).	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The	  CALGB	  “intermediate”	  cytogenetic	  risk	  group	  includes	  over	  a	  dozen	  specific	  
karyotypes	  including	  normal	  karyotypes,	  -­‐Y,	  t(9,11),	  del(5q),	  +11,	  +13.	  The	  
“adverse”	  risk	  group	  includes	  patients	  with	  complex	  karyotypes,	  defined	  by	  three	  or	  
more	  abnormalities.	  Complex	  karyotypes	  are	  seen	  in	  10-­‐12%	  of	  AML	  cases	  (24).	  
Additional	  CALGB	  “adverse”	  abnormalities	  includes	  inv(3),	  t(3;3),	  and	  -­‐7	  (22,23).	  
Other	  groups	  have	  documented	  additional	  poor	  prognosis	  karyotypes	  including	  −5,	  
del(5q),	  and	  −7	  (25).	  A	  separate	  large	  study	  divided	  patients	  into	  two	  groups:	  
cytogenetically	  normal	  or	  good	  prognosis	  karyotype	  versus	  poor	  prognosis	  
karyotype.	  In	  the	  normal	  or	  good	  group,	  median	  survival	  was	  90	  weeks	  compared	  to	  
40	  weeks	  in	  the	  negative	  karyotype	  group.	  Survival	  at	  2	  years	  was	  also	  significantly	  
better	  in	  the	  normal	  or	  good	  group,	  46%	  versus	  20%	  in	  the	  poor	  group	  (26).	  
	  
While	  there	  are	  believed	  to	  be	  biological	  differences	  between	  pediatric	  and	  adult	  
AML,	  the	  reasons	  for	  the	  differences	  are	  largely	  unknown.	  Age	  is	  strongly	  associated	  
with	  abnormal	  karyotypes	  in	  AML.	  In	  several	  large	  studies	  including	  thousands	  of	  
patients,	  55%	  of	  adults	  and	  76%	  of	  children	  with	  AML	  were	  found	  to	  have	  abnormal	  
karyotypes	  (21).	  It	  is	  well	  established	  that	  some	  chromosomal	  abnormalities	  are	  
linked	  to	  particular	  ages.	  For	  example,	  11q23	  rearrangements	  are	  detected	  in	  43-­‐
58%	  of	  infants	  aged	  twelve	  months	  or	  less	  (27)	  while	  this	  rearrangement	  is	  found	  in	  
5%	  of	  adults	  with	  AML	  aged	  15-­‐34	  and	  1%	  of	  patients	  older	  than	  55	  years	  (28).	  	  
	  
The	  cytogenetic	  abnormalities	  more	  commonly	  found	  in	  older	  patients	  are	  more	  
likely	  to	  indicate	  poor	  prognosis	  (29).	  A	  study	  of	  968	  adult	  patients	  demonstrated	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younger	  patients	  had	  more	  favorable	  karyotypes.	  Cytogenetic	  risk	  was	  classified	  
into	  favorable,	  intermediate	  and	  unfavorable	  categories.	  In	  patients	  younger	  than	  56	  
years,	  16%	  had	  a	  favorable	  karyotype	  and	  33%	  had	  an	  unfavorable	  karyotype.	  
However,	  in	  patients	  older	  than	  75	  years,	  only	  4%	  had	  a	  favorable	  karyotype	  while	  
50%	  had	  an	  unfavorable	  karyotype	  (19).	  	  
	  
Genetic	  mutations	  
As	  with	  cytogenetics,	  genetic	  mutations	  have	  significant	  prognostic	  value.	  The	  45%	  
of	  AML	  patients	  with	  normal	  cytogenetics	  was	  found	  to	  have	  divergent	  outcomes.	  
Whole	  exome	  sequencing	  identified	  recurrent	  gene	  mutations	  and	  has	  become	  
important	  in	  predicting	  clinical	  outcomes	  in	  this	  group	  that	  is	  cytogenetically	  
normal	  but	  heterogeneous	  at	  the	  molecular	  level.	  	  For	  example,	  patients	  with	  an	  
internal	  tandem	  duplication	  of	  the	  FLT3	  gene	  have	  a	  worse	  prognosis	  (30,31).	  Yet	  
patients	  with	  the	  NPM1	  mutation	  (32),	  DNMT3A	  mutation,	  and	  CEBPA	  biallelic	  
mutations	  have	  higher	  rates	  of	  complete	  remission	  and	  overall	  survival	  (6,31).	  The	  
European	  LeukemiaNet	  standard	  reporting	  system	  categorizes	  patients	  using	  
cytogenetic	  analysis	  and	  mutation	  analyses	  of	  the	  NPM1,	  CEBPA,	  and	  FLT3	  genes.	  
The	  resulting	  groups	  are	  favorable,	  intermediate-­‐I,	  intermediate-­‐II,	  and	  adverse	  (6).	  	  
	  
New	  technology	  in	  gene	  expression	  profiling	  is	  attempting	  for	  further	  classify	  AML	  
and	  predict	  prognosis	  but	  at	  this	  time	  is	  only	  experimental	  and	  not	  used	  in	  a	  clinical	  
setting.	  Many	  groups	  are	  using	  microarrays	  on	  large	  numbers	  of	  AML	  patients	  to	  
further	  understand	  gene	  expression	  signatures	  (33-­‐35).	  For	  example,	  using	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microarray,	  one	  group	  was	  able	  to	  separate	  cytogenetically	  normal	  patients	  into	  two	  
subgroups	  based	  on	  morphology	  and	  FLT3	  mutations.	  These	  subgroups	  were	  found	  
to	  be	  strongly	  independent	  prognostic	  factors	  (36).	  	  Similarly,	  groups	  are	  using	  
microRNA	  expression	  profiles	  for	  classification	  and	  prognostic	  purposes	  (37-­‐39).	  
	  
Response	  to	  chemotherapy	  
Response	  to	  chemotherapy	  represents	  an	  additional	  prognostic	  factor	  in	  older	  AML	  
patients.	  Some	  of	  the	  reasons	  for	  therapeutic	  resistance	  are	  noted	  above,	  such	  as	  
adverse	  cytogenetics,	  AML	  with	  myelodysplasia-­‐related	  changes	  subtype	  and	  
reduced	  performance	  status.	  Yet	  another	  factor	  is	  the	  presence	  of	  the	  multidrug	  
resistance	  glycoprotein	  MDR1	  that	  encodes	  a	  transmembrane	  efflux	  pump.	  This	  
pump	  removes	  chemotherapeutic	  compounds	  such	  as	  anthracyclines	  from	  leukemic	  
cells	  and	  is	  associated	  with	  poorer	  outcomes	  (40,41).	  	  Older	  patients	  have	  the	  
highest	  rates	  of	  intrinsic	  drug	  resistance;	  in	  one	  study,	  71%	  were	  found	  to	  have	  
MDR1	  protein	  expression	  and	  58%	  were	  found	  to	  have	  functional	  drug	  efflux	  (11).	  
Elderly	  patients	  without	  MDR1	  had	  a	  complete	  remission	  rate	  of	  68%	  versus	  32%	  in	  
those	  with	  MDR1	  (11).	  	  
	  
Treatment	  
Chemotherapy	  with	  the	  goal	  of	  inducing	  remission	  is	  typically	  recommended	  in	  all	  
otherwise	  healthy	  older	  adults,	  as	  AML	  patients	  who	  achieve	  remission	  have	  been	  
shown	  to	  have	  improved	  long-­‐term	  survival	  and	  quality	  of	  life	  compared	  with	  those	  
who	  receive	  only	  palliative	  therapy	  (4).	  	  Improved	  quality	  of	  life	  for	  those	  achieving	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remission	  includes	  fewer	  hospitalizations,	  transfusions,	  and	  courses	  of	  antibiotics	  
(4).	  Furthermore,	  relapse	  is	  unlikely	  in	  patients	  of	  any	  age	  who	  achieve	  and	  
maintain	  complete	  remission	  for	  3-­‐4	  years	  (42).	  
	  
Standard	  induction	  chemotherapy	  
The	  current	  standard	  for	  induction	  chemotherapy	  in	  elderly	  patients	  is	  seven	  days	  
of	  continuous	  infusion	  of	  the	  antimetabolic	  agent	  cytarabine	  plus	  three	  days	  of	  an	  
anthracycline	  such	  as	  idarubicin	  or	  daunorubicin	  (43).	  As	  with	  any	  patient	  
population,	  it	  is	  necessary	  to	  balance	  response	  and	  toxicity	  for	  chemotherapy	  dosing	  
regimens.	  In	  older	  patients	  with	  AML	  this	  is	  especially	  difficult	  as	  the	  disease	  is	  
more	  resistant	  to	  therapy	  yet	  the	  patients	  are	  more	  susceptible	  to	  the	  toxicities	  (44).	  
	  
A	  recent	  study	  of	  AML	  patients	  between	  the	  ages	  of	  60	  and	  83	  demonstrated	  that	  
doubling	  the	  dosage	  of	  daunorubicin	  from	  the	  previous	  conventional	  dose	  had	  
higher	  rates	  of	  remission	  after	  the	  first	  cycle	  (52%	  versus	  35%),	  higher	  rates	  of	  
complete	  remission	  (73%	  versus	  51%)	  and	  overall	  survival	  (38%	  versus	  23%).	  
Furthermore,	  the	  toxicity	  profiles	  of	  the	  conventional	  and	  double	  doses	  were	  similar	  
(43).	  However,	  other	  studies	  have	  failed	  to	  support	  higher	  doses	  of	  chemotherapy.	  
In	  another	  study	  of	  patients	  over	  age	  60,	  dosages	  of	  daunorubicin	  and	  cytarabine	  
were	  increased	  and	  a	  fourth	  course	  of	  treatment	  was	  added.	  Complete	  remission	  
was	  observed	  in	  54%	  of	  patients	  and	  no	  survival	  benefit	  was	  observed	  by	  increasing	  
dosages	  or	  treatments.	  Only	  increased	  mortality	  was	  observed	  among	  patients	  




Due	  to	  the	  significant	  toxicities	  of	  induction	  chemotherapy,	  supportive	  care	  is	  
typically	  recommended	  in	  older	  patients	  with	  severe	  comorbidities,	  high	  risk	  
disease	  and	  indolent	  disease	  (4,46,47).	  This	  leaves	  64%	  of	  patients	  over	  the	  age	  of	  
65	  with	  AML	  who	  are	  not	  treated	  and	  have	  a	  median	  survival	  of	  only	  1.7	  months	  
(48).	  
	  
Low	  intensity	  treatment	  
Compared	  to	  full	  strength	  induction	  treatment,	  low	  intensity	  treatment	  reduces	  the	  
chance	  of	  obtaining	  complete	  remission,	  often	  resulting	  in	  reduced	  survival	  times	  
(49).	  In	  one	  study,	  87	  patients	  over	  age	  65	  with	  AML	  were	  randomly	  assigned	  to	  
receive	  low	  dose	  cytarabine	  or	  intensive	  chemotherapy.	  Patients	  in	  the	  intensive	  
group	  were	  more	  likely	  to	  achieve	  complete	  remission	  but	  also	  more	  likely	  to	  have	  
infectious	  complications,	  longer	  hospital	  stays	  and	  early	  death.	  	  In	  this	  study,	  there	  
was	  no	  significant	  difference	  in	  overall	  survival	  (44).	  For	  many	  patients,	  low	  
intensity	  treatment	  is	  the	  only	  option.	  	  Efforts	  have	  been	  made	  to	  risk-­‐stratify	  
patients	  and	  administer	  low-­‐dose	  therapy	  to	  spare	  those	  with	  a	  low	  probability	  of	  
survival	  benefit	  from	  toxic	  treatment.	  Unfortunately,	  most	  studies	  have	  been	  
disappointing	  in	  improving	  overall	  survival	  (50).	  One	  trial	  of	  217	  patients	  unfit	  for	  
intensive	  chemotherapy	  were	  randomized	  to	  receive	  either	  low-­‐dose	  cytarabine	  or	  
hydroxyurea.	  Patients	  in	  the	  low	  dose	  cytarabine	  group	  had	  a	  higher	  rate	  of	  
complete	  remission	  (18%	  versus	  1%)	  with	  similar	  toxicity	  profiles.	  Yet	  in	  both	  




Clinical	  trials	  are	  ongoing	  with	  newer	  chemotherapeutic	  agents	  including	  
cloretazine	  (52),	  farnesyl	  transferase	  inhibitors,	  clofarabine	  and	  lenalidomide	  (53).	  
The	  antineoplastic	  agent	  mitoxantrone	  in	  combination	  with	  cytarabine	  as	  well	  as	  
the	  combination	  of	  daunorubicin,	  cytarabine,	  and	  etoposide	  were	  both	  found	  to	  be	  
inferior	  to	  the	  combination	  of	  daunorubicin,	  cytarabine,	  and	  thioguanine	  (54).	  Other	  
unsuccessful	  trials	  used	  the	  tyrosine	  kinase	  inhibitor	  imatinib	  (55)	  and	  the	  P-­‐
glycoprotein	  modulators	  valspodar	  and	  zosuquidar	  (56,57).	  The	  conjugated	  anti-­‐
CD33	  antibody	  gemtuzumab	  ozogamicin	  was	  approved	  for	  the	  treatment	  of	  elderly	  
patients	  with	  relapsed	  AML	  (58)	  and	  demonstrated	  effectiveness	  as	  a	  first	  line	  
therapy	  in	  elderly	  patients	  (59).	  However,	  it	  has	  since	  been	  withdrawn	  from	  the	  
market	  due	  to	  high	  levels	  of	  hepatic	  toxicity	  (60).	  
	  
Hypomethylating	  agents	  
Drugs	  used	  in	  the	  treatment	  of	  MDS	  have	  been	  trialed	  in	  patients	  with	  AML	  with	  
promising	  results.	  Azacitidine	  and	  decitabine	  are	  nucleoside	  analogues	  that	  
incorporate	  into	  DNA	  and	  RNA	  and	  also	  inhibit	  DNA	  methyltransferase.	  By	  
inhibiting	  methylation,	  these	  drugs	  are	  able	  to	  re-­‐activate	  genes,	  notably	  tumor	  
suppressor	  genes	  silenced	  by	  DNA	  hypermethylation	  (61).	  Azacitidine	  and	  
decitabine	  are	  thereby	  able	  to	  have	  a	  dual	  effect:	  at	  low	  levels	  they	  induce	  
differentiation	  in	  AML	  cells	  while	  at	  high	  doses	  they	  trigger	  apoptosis	  via	  DNA	  
synthesis	  arrest	  (62).	  Azacitidine	  was	  found	  to	  increase	  overall	  survival	  in	  patients	  
with	  higher-­‐risk	  MDS	  or	  AML	  when	  compared	  to	  conventional	  regimens	  (63).	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Outcomes	  equivalent	  to	  standard	  chemotherapy	  have	  been	  observed	  with	  
decitabine	  in	  patients	  who	  are	  not	  candidates	  for	  aggressive	  therapy	  (64).	  	  
	  
A	  Phase	  I	  study	  in	  2004	  demonstrated	  that	  decitabine	  was	  more	  effective	  at	  lower	  
doses,	  the	  optimal	  being	  15mg/m2	  intravenously	  over	  one	  hour	  daily,	  5	  days	  a	  week,	  
for	  a	  total	  of	  two	  weeks	  (65).	  Early	  studies	  using	  a	  range	  of	  low	  dose	  decitabine	  
regimens	  demonstrated	  overall	  response	  rates	  of	  17%	  to	  44%	  in	  patients	  with	  AML	  
and	  MDS	  (65-­‐68).	  A	  study	  of	  95	  patients	  with	  MDS	  and	  chronic	  myelomonocytic	  
leukemia	  used	  three	  decitabine	  regimens:	  20	  mg/m2	  intravenously	  daily	  for	  5	  days;	  
20	  mg/m2	  subcutaneously	  daily	  for	  5	  days;	  and	  10	  mg/m2	  intravenously	  daily	  for	  10	  
days.	  The	  high	  dose	  intravenous	  schedule	  had	  the	  highest	  complete	  response	  rate	  of	  
39%,	  compared	  with	  21%	  in	  the	  subcutaneous	  group	  and	  24%	  in	  the	  10	  day	  group	  
(69).	  	  
	  
Decitabine	  in	  older	  patients	  
In	  2010,	  results	  were	  published	  from	  the	  first	  study	  of	  older	  AML	  patients	  using	  
decitabine	  as	  a	  first-­‐line	  treatment.	  This	  multicenter	  phase	  II	  study	  enrolled	  55	  
patients	  over	  the	  age	  of	  60	  years	  with	  a	  median	  age	  of	  74	  years.	  The	  patient	  profile	  
was	  high-­‐risk,	  as	  would	  be	  expected	  of	  older	  patients;	  45%	  had	  poor	  risk	  
cytogenetics	  and	  35%	  had	  AML	  transformed	  from	  MDS.	  	  The	  treatment	  regimen	  was	  
decitabine	  20mg/m2	  intravenously	  for	  five	  days	  every	  four	  weeks.	  Patients	  were	  
treated	  with	  a	  median	  three	  cycles	  of	  decitabine	  treatment,	  and	  64%	  of	  patients	  
received	  three	  or	  more	  cycles.	  The	  overall	  complete	  response	  rate	  was	  25%,	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including	  20%	  in	  patients	  with	  poor	  risk	  cytogenetics	  and	  21%	  in	  patients	  with	  a	  
prior	  history	  of	  MDS.	  An	  additional	  29%	  of	  patients	  who	  did	  not	  achieve	  CR	  
maintained	  stable	  or	  improved	  bone	  marrow	  blast	  counts	  through	  a	  median	  five	  
cycles	  of	  therapy.	  At	  least	  one	  serious	  adverse	  event	  was	  experienced	  by	  47%	  of	  
patients,	  with	  the	  most	  serious	  toxicities	  being	  myelosuppression,	  febrile	  
neutropenia,	  and	  fatigue.	  The	  overall	  median	  survival	  was	  7.7	  months	  (70).	  	  
	  
Further	  studies	  have	  demonstrated	  favorable	  results	  with	  the	  use	  of	  decitabine	  in	  
older	  patients.	  Patients	  over	  the	  age	  of	  60	  with	  previously	  untreated	  AML	  who	  
refused	  or	  were	  not	  candidates	  for	  intensive	  chemotherapy	  received	  low-­‐dose	  
decitabine	  using	  a	  previously	  untested	  ten-­‐day	  therapy	  schedule.	  	  With	  53	  patients	  
enrolled,	  47%	  achieved	  a	  complete	  remission	  and	  an	  additional	  17%	  achieved	  a	  
morphologic	  leukemia-­‐free	  state	  with	  incomplete	  count	  recovery.	  Median	  overall	  
survival	  for	  all	  patients	  was	  55	  weeks.	  This	  study	  also	  investigated	  the	  relationship	  
between	  clinical	  response	  with	  decitabine	  and	  pretreatment	  levels	  of	  miR-­‐29b,	  a	  
microRNA	  known	  to	  target	  DNA	  methyltransferase.	  Of	  the	  23	  patients	  with	  available	  
pretreatment	  samples,	  a	  statistically	  significant	  association	  was	  made	  between	  
those	  who	  responded	  to	  decitabine	  treatment	  and	  higher	  pretreatment	  levels	  of	  
miR-­‐29b.	  It	  is	  theorized	  that	  higher	  levels	  of	  miR-­‐29b	  lead	  to	  a	  lower	  pre-­‐treatment	  
level	  of	  DNA	  methyltransferase	  and	  increased	  sensitivity	  to	  decitabine’s	  
hypomethylating	  effects	  (71).	  
	  
Two	  large	  studies	  published	  in	  2012	  examined	  decitabine	  in	  older	  AML	  patients.	  In	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a	  multicenter,	  randomized,	  open-­‐label	  phase	  III	  trial	  of	  485	  patients,	  decitabine	  
improved	  response	  rates	  (17.8%	  versus	  7.8%)	  and	  overall	  survival	  (7.7	  months	  
versus	  5.0	  months)	  when	  compared	  to	  a	  treatment	  choice	  group	  receiving	  
supportive	  care	  or	  cytarabine	  (72).	  A	  retrospective	  study	  of	  671	  patients	  compared	  
intensive	  thermotherapy	  with	  azacitidine	  or	  decitabine	  therapy.	  The	  complete	  
response	  rate	  was	  superior	  in	  the	  intensive	  chemotherapy	  group	  (42%	  versus	  28%)	  
but	  the	  median	  survival	  was	  equivalent	  (6.7	  months	  versus	  6.5	  months).	  
Multivariate	  analysis	  demonstrated	  age,	  cytogenetics	  and	  performance	  status	  but	  
not	  type	  of	  therapy	  as	  independent	  prognostic	  factors.	  Notably,	  decitabine	  was	  
associated	  with	  improved	  median	  survival	  when	  compared	  with	  azacitidine	  (8.8	  
months	  versus	  5.5	  months)	  (73).	  	  
	  
Older	  patients	  with	  AML	  present	  unique	  challenges;	  both	  the	  disease	  and	  the	  health	  
of	  the	  patient	  are	  different	  than	  that	  of	  younger	  patients.	  Older	  AML	  patients	  have	  
forms	  of	  the	  disease	  that	  carry	  a	  worse	  prognosis	  such	  as	  poor	  risk	  cytogenetics	  and	  
a	  history	  of	  MDS.	  Older	  patients	  also	  have	  inferior	  functional	  status	  and	  are	  less	  able	  
to	  tolerate	  intensive	  chemotherapy.	  Too	  many	  older	  AML	  patients	  never	  undergo	  
chemotherapy	  and	  those	  that	  do	  have	  poor	  rates	  of	  complete	  remission	  and	  short	  
survival	  times.	  Better	  therapies	  for	  older	  AML	  patients	  are	  needed;	  trials	  using	  
different	  dosing	  schedules	  and	  new	  drugs	  aimed	  specifically	  at	  this	  population	  
group	  are	  ongoing.	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STATEMENT	  OF	  PURPOSE	  SPECIFIC	  HYPOTHESIS	  AND	  SPECIFIC	  AIMS	  OF	  THE	  THESIS	  
	  
Overall	   survival	   in	  older	  patients	  with	  AML	   is	  poor,	   so	   improving	  quality	  of	   life	   in	  
this	  patient	  population	  is	  an	  important	  goal.	  It	  is	  hypothesized	  that	  in	  older	  patients	  
with	  AML	   the	   reduced	   intensity	   chemotherapeutic	   agent	   decitabine	   is	   superior	   to	  
standard	  induction	  chemotherapy	  or	  supportive	  care	  only.	  
	  
The	   aim	   of	   this	   study	   is	   to	   determine	   whether	   improved	   quality	   of	   life	   can	   be	  
achieved	   in	   older	   patients	   with	   AML	   using	   reduced	   intensity	   chemotherapy.	  
Surrogates	   for	   quality	   of	   life	   include	   number	   of	   days	   spent	   in	   the	   hospital	   and	  
number	  of	  outpatient	  visits.	  Other	  metrics	  by	  which	  to	  measure	  the	  effectiveness	  of	  
the	   chemotherapeutic	   agents	   include	   overall	   survival,	   achievement	   of	   complete	  
remission,	  and	  early	  death.	  	  
	  






A	  request	  for	  approval	  of	  medical	  record	  review	  was	  made	  with	  the	  Yale	  University	  
Human	  Investigation	  Committee	  (HIC).	  The	  projected	  aim	  of	  the	  study	  was	  to	  
compare	  the	  treatment	  of	  a	  group	  of	  individuals	  65	  years	  or	  older	  with	  AML	  treated	  
with	  the	  hypomethylating	  agents	  5-­‐azacitidine	  or	  decitabine	  with	  a	  control	  group	  of	  
individuals	  with	  AML	  treated	  with	  other	  chemotherapeutic	  agents.	  Outcomes	  to	  be	  
measured	  included	  hospitalizations,	  outpatient	  visits,	  and	  overall	  survival.	  Records	  
were	  requested	  from	  Yale-­‐New	  Haven	  Hospital	  (YNHH)	  and	  Yale	  Cancer	  Center	  of	  
all	  patients,	  both	  inpatient	  and	  outpatient,	  age	  65	  and	  older	  treated	  for	  AML	  
(diagnosis	  codes	  205.00	  and	  205.01)	  from	  January	  1,	  2000	  through	  December	  31,	  
2009.	  Electronic	  records	  to	  be	  interrogated	  included	  the	  admission/discharge	  
database,	  Sunrise	  Clinical	  Manager,	  and	  Centricity.	  Data	  requested	  included	  
diagnosis	  codes,	  medical	  record	  number	  and	  age.	  The	  study	  was	  given	  HIC	  protocol	  
#	  1006006963.	  The	  project	  was	  determined	  to	  be	  exempt	  from	  HIC	  review,	  as	  it	  
involved	  the	  collection	  and	  study	  of	  existing	  data	  and	  records	  and	  was	  to	  be	  
recorded	  in	  such	  a	  manner	  in	  which	  subjects	  cannot	  be	  identified,	  directly	  or	  
through	  identifiers	  linked	  to	  the	  subjects.	  
	  
Patient	  Selection	  
Inclusion	  criteria	  were	  patients	  age	  65	  years	  of	  older	  with	  primary	  diagnosis	  of	  AML	  
who	  received	  first	  line	  treatment	  with	  decitabine,	  standard	  induction	  chemotherapy	  
of	  cytarabine	  and	  idarubicin,	  or	  supportive	  care	  only.	  Exclusion	  criteria	  included	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patients	  who	  had	  prior	  cancer	  diagnoses	  and	  received	  other	  first	  line	  
chemotherapeutic	  agents.	  YNHH	  provided	  a	  spreadsheet	  for	  every	  inpatient	  and	  
outpatient	  visit	  with	  an	  AML	  diagnosis	  code.	  This	  spreadsheet	  included	  the	  
following	  data:	  medical	  record	  number,	  encounter	  number,	  name,	  sex,	  race	  
description,	  age,	  inpatient	  or	  outpatient	  encounter,	  admission	  date,	  discharge	  date,	  
length	  of	  stay,	  principal	  ICD-­‐9	  code	  and	  description,	  secondary	  diagnoses	  by	  visit,	  
and	  date	  of	  death	  (if	  at	  YNHH).	  	  The	  spreadsheet	  also	  indicated	  whether	  the	  
following	  medications	  were	  used:	  5-­‐azacitidine,	  decitabine,	  cytarabine,	  doxorubicin,	  
idarubicin,	  and	  gemtuzumab.	  
	  
From	  the	  initial	  list	  of	  patient	  visits,	  276	  unique	  patients	  were	  identified	  (Figure	  1).	  
Of	  these	  patients,	  58	  patients	  were	  identified	  with	  primary	  AML	  diagnoses	  treated	  
at	  YNHH.	  The	  other	  218	  patients	  were	  excluded	  for	  the	  following	  reasons:	  49	  
patients	  were	  treated	  elsewhere	  and	  seen	  at	  YNHH	  in	  consultation	  or	  for	  laboratory	  
purposes	  only;	  21	  patients	  had	  MDS	  but	  did	  not	  meet	  the	  criteria	  for	  AML;	  62	  
patients	  had	  a	  prior	  history	  or	  primary	  diagnosis	  of	  another	  leukemia	  or	  lymphoma;	  
27	  patients	  were	  either	  already	  in	  remission	  or	  had	  relapsed	  AML;	  17	  patients	  had	  a	  
primary	  diagnosis	  of	  a	  solid	  tumor;	  36	  patients	  had	  no	  accessible	  medical	  record	  or	  
no	  mention	  of	  AML	  in	  their	  record;	  and	  6	  patients	  had	  an	  initial	  AML	  diagnosis	  
before	  age	  65.	  
	  
Of	  the	  58	  patients	  with	  primary	  AML	  diagnosis	  after	  age	  65	  treated	  at	  YNHH,	  20	  
received	  decitabine	  therapy.	  Of	  those,	  11	  received	  decitabine	  alone	  as	  first-­‐line	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therapy	  while	  eight	  patients	  received	  it	  as	  second	  line	  treatment	  and	  one	  patient	  
received	  decitabine	  and	  gemtuzumab	  ozogamicin	  in	  combination.	  The	  38	  remaining	  
patients	  never	  received	  decitabine	  treatment.	  Of	  that	  group,	  14	  patients	  never	  
received	  chemotherapeutic	  treatment.	  Eleven	  patients	  received	  standard	  induction	  




Three	  patient	  groups	  were	  identified	  for	  further	  data	  analysis.	  These	  include	  11	  
patients	  who	  received	  standard	  induction	  therapy	  of	  cytarabine	  and	  idarubicin,	  11	  
patients	  who	  received	  decitabine	  alone	  as	  first	  line	  therapy,	  and	  14	  patients	  who	  
received	  no	  chemotherapeutic	  treatment.	  
	  
Data	  Collection	  
Collected	  raw	  data	  included	  date	  of	  diagnosis,	  date	  of	  death,	  number	  of	  cycles	  of	  
chemotherapeutic	  treatment,	  number	  of	  days	  spent	  in	  the	  hospital,	  number	  of	  
outpatient	  visits,	  cytogenetics	  and	  flow	  cytometry	  at	  time	  of	  diagnosis,	  complete	  
blood	  count	  with	  differential	  at	  time	  of	  diagnosis,	  and	  use	  of	  other	  
chemotherapeutic	  agents	  or	  hydroxyurea.	  Survival	  in	  months	  was	  calculated	  from	  
date	  of	  diagnosis	  to	  date	  of	  death.	  When	  not	  available	  through	  the	  YNHH	  medical	  






Statistics	  and	  graphs	  were	  generated	  using	  Microsoft	  Excel.	  P-­‐values	  were	  
calculated	  using	  a	  two-­‐tailed,	  unpaired	  Student’s	  t-­‐test.	  P-­‐values	  <	  0.05	  were	  
considered	  significant.	  Confidence	  intervals	  were	  calculated	  using	  an	  α	  of	  0.05.	  
Kaplan-­‐Meier	  curves	  were	  generated	  using	  XLSTAT-­‐Life	  Survival	  Analysis	  Software	  
(Addinsoft,	  Paris,	  France)	  based	  on	  [Gehan	  EA.	  A	  generalized	  Wilcoxon	  test	  for	  
comparing	  arbitrarily	  singly-­‐censored	  samples.	  Biometrika	  1965;52:203-­‐23].	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Between	  January	  2000	  and	  December	  2010,	  58	  patients	  age	  65	  or	  older	  had	  new	  
diagnoses	  of	  AML	  (Figure	  1).	  Of	  these	  patients,	  eleven	  received	  first-­‐line	  treatment	  
of	  idarubicin	  and	  cytarabine	  standard	  induction	  chemotherapy;	  eleven	  received	  
first-­‐line	  treatment	  with	  decitabine;	  and	  fourteen	  received	  supportive	  care.	  	  
	  
Patient	  demographics	  and	  baseline	  clinical	  characteristics	  were	  not	  balanced	  among	  
the	  three	  treatment	  groups	  (Table	  1).	  The	  standard	  induction	  chemotherapy	  group	  
was	  the	  youngest	  with	  a	  median	  age	  of	  69	  years	  (range,	  65	  to	  76	  years);	  this	  group	  
was	  nearly	  evenly	  split	  with	  six	  patients	  in	  their	  sixties	  and	  five	  patients	  in	  their	  
seventies.	  The	  decitabine	  group	  was	  statistically	  significantly	  older	  (P	  =	  .020)	  with	  a	  
median	  age	  of	  77	  years	  (range,	  67	  to	  87	  years);	  only	  three	  of	  the	  patients	  were	  in	  
their	  sixties	  while	  seven	  patients	  were	  in	  their	  seventies	  and	  one	  patient	  was	  87	  
years	  old.	  The	  supportive	  care	  group	  was	  the	  oldest	  and	  statistically	  significantly	  
older	  (P	  =	  .0005)	  than	  the	  decitabine	  group	  with	  a	  median	  age	  of	  84.5	  (range,	  75	  to	  
89	  years).	  No	  patients	  receiving	  only	  supportive	  care	  were	  in	  their	  sixties	  and	  only	  
three	  were	  in	  their	  seventies.	  The	  other	  eleven	  patients	  were	  all	  in	  their	  eighties.	  	  
	  
There	  were	  more	  men	  in	  the	  standard	  chemotherapy	  (eight	  men,	  three	  women)	  and	  
decitabine	  (seven	  men,	  four	  women)	  groups,	  but	  gender	  was	  evenly	  balanced	  in	  the	  




There	  were	  no	  statistically	  significant	  differences	  in	  complete	  blood	  counts	  upon	  
initial	  diagnosis	  in	  the	  three	  treatment	  groups.	  The	  median	  white	  blood	  cell	  (WBC)	  
count	  in	  all	  three	  groups	  was	  equal	  to	  or	  less	  than	  5.0	  x	  109/L.	  Median	  WBC	  counts	  
at	  diagnosis	  were	  4.8	  x	  109/L	  (95%	  confidence	  interval	  (CI),	  -­‐5.3	  to	  62.6	  x	  109/L)	  in	  
the	  standard	  chemotherapy	  group;	  1.9	  x	  109/L	  (95%	  CI,	  1.5	  to	  11.9	  x	  109/L)	  in	  the	  
decitabine	  group,	  and	  5.0	  x	  109/L	  (95%	  CI,	  0.7	  to	  56.1	  x	  109/L)	  in	  the	  no	  treatment	  
group.	  Three	  (27.3%)	  patients	  in	  the	  standard	  chemotherapy	  group,	  two	  (18.2%)	  
patients	  in	  the	  decitabine	  group,	  and	  four	  (28.6%)	  patients	  in	  the	  supportive	  care	  
group	  had	  initial	  WBC	  counts	  greater	  than	  10	  x	  109/L.	  	  
	  
Initial	  median	  hemoglobin	  was	  nearly	  equivalent	  in	  the	  standard	  induction	  
chemotherapy	  (9.3	  g/dL;	  95%	  CI,	  8.1	  to	  10.7	  g/dL)	  and	  decitabine	  (9.0	  g/dL;	  95%	  
CI,	  7.2	  to	  10.3	  g/dL)	  groups	  but	  statistically	  insignificantly	  lower	  in	  the	  supportive	  
care	  group	  at	  7.5	  g/dL	  (95%	  CI	  6.5	  to	  8.3	  g/dL).	  Median	  platelet	  counts	  upon	  initial	  
diagnosis	  were	  92,000/μL	  (95%	  CI,	  59,000	  to	  125,000/μL)	  in	  the	  standard	  
chemotherapy	  group,	  46,000/μL	  (95%	  CI,	  27,000	  to	  119,000/μL)	  in	  the	  decitabine	  
group,	  and	  66,000/μL	  (95%	  CI,	  48,000	  to	  137,000/μL)	  in	  the	  supportive	  care	  group.	  
	  
The	  standard	  induction	  chemotherapy	  group	  and	  decitabine	  group	  had	  similar	  
cytogenetic	  profiles,	  as	  stratified	  by	  the	  Cancer	  and	  Leukemia	  Group	  B	  into	  
favorable,	  intermediate,	  or	  adverse	  cytogenetic	  risk	  groups	  (22).	  The	  standard	  
induction	  chemotherapy	  group	  had	  one	  patient	  with	  favorable	  cytogenetics,	  five	  
patients	  with	  intermediate	  cytogenetics,	  and	  four	  patients	  with	  adverse	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cytogenetics.	  One	  patient’s	  cytogenetics	  is	  unavailable.	  The	  decitabine	  group	  had	  
five	  patients	  with	  intermediate	  cytogenetics	  and	  five	  patients	  with	  adverse	  
cytogenetics.	  Again,	  one	  patient’s	  cytogenetics	  is	  unavailable.	  The	  supportive	  care	  
group	  only	  had	  five	  patients	  with	  available	  cytogenetic	  information.	  Of	  those,	  three	  
had	  intermediate	  and	  two	  had	  adverse	  cytogenetic	  risk.	  
	  
Treatment	  regimens	  
All	  11	  patients	  in	  the	  standard	  induction	  chemotherapy	  group	  received	  a	  cytarabine	  
and	  idarubicin	  7	  plus	  3	  regimen	  for	  remission	  induction	  of	  AML.	  On	  a	  28	  day	  cycle,	  
this	  regimen	  calls	  for	  IV	  idarubicin	  on	  days	  1,	  2,	  and	  3	  and	  continuous	  IV	  infusion	  of	  
cytarabine	  on	  days	  1	  through	  7.	  	  
	  
Three	  patients	  (27.3%)	  achieved	  complete	  remission	  and	  subsequently	  received	  
cytarabine	  consolidation	  treatment	  (Table	  2).	  Four	  patients	  (36.4%)	  were	  
refractory	  to	  the	  initial	  cytarabine	  and	  idarubicin	  7	  +	  3	  regimen	  and	  received	  other	  
chemotherapeutic	  agents.	  One	  received	  two	  courses	  of	  high-­‐dose	  cytarabine	  
(HIDAC)	  and	  achieved	  complete	  remission	  that	  was	  followed	  by	  cytarabine	  
consolidation	  treatment.	  Another	  patient	  achieved	  remission	  after	  receiving	  the	  
FLAG	  regimen	  of	  fludarabine,	  cytarabine,	  and	  granulocyte	  colony-­‐stimulating	  factor	  
(G-­‐CSF).	  Two	  more	  patients	  received	  one	  cycle	  of	  gemtuzumab	  ozogamicin	  and	  
never	  achieved	  remission.	  None	  of	  the	  patients	  who	  received	  standard	  induction	  




The	  11	  patients	  in	  the	  decitabine	  group	  received	  a	  median	  five	  cycles	  of	  decitabine	  
(95%	  CI,	  3.7	  to	  8.0	  cycles)	  given	  over	  the	  course	  of	  five	  days	  every	  four	  or	  five	  
weeks.	  One	  patient	  died	  and	  was	  unable	  to	  complete	  the	  first	  cycle.	  All	  other	  
patients	  received	  a	  minimum	  three	  cycles.	  The	  highest	  number	  of	  cycles	  received	  
was	  thirteen.	  
	  
No	  patients	  receiving	  decitabine	  ever	  achieved	  a	  documented	  remission.	  Five	  
patients	  proceeded	  to	  other	  chemotherapeutic	  agents.	  Four	  received	  gemtuzumab	  
ozogamicin	  and	  one	  received	  clofarabine.	  Five	  of	  the	  eleven	  patients	  in	  the	  
decitabine	  group	  also	  received	  hydroxyurea.	  The	  patients	  in	  the	  supportive	  care	  
group	  received	  no	  chemotherapeutic	  agents,	  but	  four	  patients	  received	  
hydroxyurea.	  There	  were	  no	  documented	  remissions	  in	  the	  supportive	  care	  group.	  	  
	  
Efficacy	  
The	  patients	  receiving	  standard	  induction	  chemotherapy	  of	  idarubicin	  and	  
cytarabine	  had	  a	  median	  overall	  survival	  of	  7	  months	  (95%	  confidence	  interval	  (CI),	  
3.5	  to	  9.4	  months)	  (Figure	  2).	  There	  was	  a	  favorable	  but	  nonsignificant	  (P	  =	  .192)	  
trend	  toward	  increased	  median	  overall	  survival	  in	  patients	  receiving	  decitabine.	  
Decitabine	  patients	  had	  a	  median	  overall	  survival	  of	  9	  months	  (95%	  CI,	  6.2	  to	  12.1	  
months).	  	  
	  
Patients	  receiving	  only	  supportive	  care	  had	  a	  median	  overall	  survival	  of	  0.6	  months	  
(95%	  CI,	  0.2	  to	  3.3	  months).	  These	  patients	  had	  statistically	  significantly	  worse	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survival	  than	  both	  the	  standard	  induction	  chemotherapy	  (P	  =	  .010)	  and	  decitabine	  
(P	  =	  .0003)	  groups.	  
	  
Hospitalization	  
There	  was	  a	  statistically	  significant	  (P	  =	  .047)	  trend	  toward	  a	  decreased	  number	  of	  
hospital	  days	  in	  patients	  receiving	  decitabine	  in	  comparison	  to	  those	  receiving	  
standard	  induction	  chemotherapy.	  The	  standard	  induction	  chemotherapy	  group	  
spent	  a	  median	  41	  days	  (95%	  CI,	  32.6	  to	  99.4	  days)	  in	  the	  hospital	  while	  the	  
decitabine	  group	  spent	  a	  median	  30	  days	  (95%	  CI,	  17.7	  to	  42.9	  days)	  in	  the	  hospital	  
(Figure	  3).	  	  
	  
When	  overall	  survival	  is	  taken	  into	  account,	  decitabine	  patients	  spent	  a	  significantly	  
smaller	  proportion	  (P	  =	  .047)	  of	  their	  lives	  in	  the	  hospital.	  To	  account	  for	  the	  
increased	  survival	  in	  the	  decitabine	  group,	  the	  number	  of	  days	  each	  patient	  spent	  in	  
the	  hospital	  was	  divided	  by	  the	  overall	  number	  of	  days	  the	  patient	  lived	  following	  
their	  AML	  diagnosis.	  Patients	  undergoing	  standard	  induction	  chemotherapy	  spent	  a	  
median	  33.1%	  (95%	  CI,	  28.7%	  to	  67.9%)	  of	  their	  time	  admitted	  in	  the	  hospital	  
while	  patients	  receiving	  decitabine	  spent	  a	  median	  8.8%	  (95%	  CI,	  4.6%	  to	  35.5%)	  of	  
their	  time	  in	  the	  hospital.	  	  
	  
Patients	  receiving	  supportive	  care	  only	  spent	  a	  median	  3.5	  days	  (95%	  CI,	  1.4	  to	  10.6	  
days)	  in	  the	  hospital.	  However,	  since	  their	  overall	  survival	  was	  reduced,	  these	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patients	  still	  spent	  a	  median	  25.0%	  (95%	  CI,	  14.7%	  to	  53.6%)	  of	  their	  days	  
following	  diagnosis	  in	  the	  hospital.	  	  
	  
Outpatient	  visits	  
Instead	  of	  spending	  more	  time	  in	  the	  hospital,	  patients	  receiving	  decitabine	  therapy	  
had	  a	  statistically	  significant	  (P	  =	  .036)	  increased	  number	  of	  outpatient	  visits	  when	  
compared	  to	  those	  receiving	  standard	  induction	  chemotherapy.	  The	  standard	  
induction	  chemotherapy	  group	  had	  a	  median	  1	  outpatient	  visit	  (95%	  CI,	  -­‐0.7	  to	  11.8	  
visits)	  while	  the	  decitabine	  group	  had	  a	  median	  12	  outpatient	  visits	  (95%	  CI,	  11.0	  to	  
75.7	  visits)	  (Figure	  3).	  	  
	  
Only	  four	  of	  the	  fourteen	  patients	  receiving	  supportive	  care	  only	  ever	  had	  a	  




Early	  death	  is	  defined	  as	  patients	  who	  die	  within	  30	  days	  of	  diagnosis	  and	  is	  used	  as	  
a	  surrogate	  for	  regimen-­‐related	  toxicity	  (22).	  Two	  patients	  (18.2%)	  receiving	  
standard	  induction	  chemotherapy	  and	  one	  patient	  (9.1%)	  receiving	  decitabine	  
experienced	  early	  death.	  Eight	  patients	  (57.1%)	  receiving	  only	  supportive	  care	  died	  




Adverse	  events	  cannot	  be	  reported	  due	  to	  the	  retrospective	  nature	  of	  this	  study	  and	  
the	  absence	  of	  comprehensive	  information	  available	  in	  the	  medical	  record.	  
	  





The	  median	  age	  of	  AML	  diagnosis	  is	  66	  years,	  yet	  older	  patients	  have	  significantly	  
worse	  prognosis.	  They	  are	  more	  likely	  to	  have	  adverse	  forms	  of	  the	  disease,	  poor	  
functional	  status,	  and	  poor	  tolerance	  for	  intensive	  chemotherapy.	  Patients	  who	  
achieve	  complete	  remission	  through	  intensive	  chemotherapy	  are	  more	  likely	  to	  
have	  increased	  survival	  and	  quality	  of	  life	  (4).	  However,	  older	  patients	  are	  less	  likely	  
to	  receive	  intensive	  chemotherapy	  and	  those	  that	  do	  are	  more	  likely	  to	  experience	  
early	  death	  and	  less	  likely	  to	  achieve	  remission	  (19,48).	  Low-­‐intensity	  and	  
alternative	  regimens	  have	  been	  trialed	  in	  older	  AML	  patients	  with	  mixed	  results	  
(50).	  One	  in	  particular,	  the	  hypomethylating	  agent	  decitabine,	  has	  demonstrated	  
complete	  remission	  rates	  ranging	  from	  25	  to	  47%.	  More	  importantly,	  decitabine	  has	  
demonstrated	  median	  survival	  in	  older	  AML	  patients	  that	  is	  comparable	  to	  other	  
chemotherapeutic	  agents	  (70-­‐72).	  	  
	  
This	  single-­‐center	  retrospective	  review	  of	  AML	  patients	  over	  age	  65	  sought	  to	  
determine	  quality	  of	  life,	  measured	  by	  hospital	  days	  and	  outpatient	  visits,	  in	  three	  
treatment	  groups:	  standard	  induction	  chemotherapy	  of	  idarubicin	  and	  cytarabine,	  
decitabine	  therapy,	  and	  supportive	  care	  only.	  	  
	  
Baseline	  characteristics	  
The	  demographics	  and	  baseline	  characteristics	  of	  the	  three	  groups	  were	  not	  
balanced.	  Those	  receiving	  standard	  induction	  chemotherapy	  were	  younger	  than	  
those	  receiving	  decitabine	  who	  in	  turn	  were	  younger	  than	  those	  receiving	  only	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supportive	  care.	  This	  is	  not	  surprising	  as	  standard	  induction	  chemotherapy	  is	  
associated	  with	  significant	  toxicities	  and	  is	  often	  poorly	  tolerated	  by	  older	  patients	  
(44).	  Decitabine	  was	  likely	  chosen	  for	  slightly	  older	  patients	  who	  still	  desired	  
treatment	  but	  were	  either	  not	  candidates	  or	  unwilling	  to	  undergo	  the	  more	  toxic	  
standard	  induction	  chemotherapy.	  The	  group	  opting	  for	  supportive	  care	  was	  
significantly	  older	  than	  the	  two	  treatment	  groups,	  with	  a	  median	  age	  of	  84.5	  years.	  It	  
is	  not	  surprising	  then	  that	  these	  patients	  were	  unwilling	  or	  unable	  to	  undergo	  any	  
treatment.	  
	  
The	  median	  WBC	  at	  diagnosis	  was	  nonsignficantly	  higher	  in	  the	  standard	  induction	  
chemotherapy	  and	  supportive	  care	  groups	  than	  the	  decitabine	  group.	  This	  could	  be	  
explained	  by	  the	  fact	  that	  elevated	  WBC	  is	  known	  to	  be	  a	  poor-­‐risk	  feature	  in	  AML	  
patients	  undergoing	  decitabine	  treatment	  (74).	  Therefore,	  it	  is	  likely	  some	  of	  the	  
patients	  with	  higher	  WBC	  were	  poor	  candidates	  for	  decitabine	  therapy	  and	  
therefore	  received	  either	  standard	  induction	  chemotherapy	  or	  supportive	  care.	  
	  
Cytogenetic	  profiles	  of	  the	  standard	  induction	  chemotherapy	  and	  decitabine	  groups	  
were	  nearly	  identical.	  The	  only	  patient	  with	  a	  favorable	  cytogenetic	  profile	  received	  
standard	  induction	  chemotherapy,	  a	  logical	  decision	  as	  this	  patient	  was	  more	  likely	  
to	  respond	  to	  the	  regimen	  and	  standard	  induction	  chemotherapy	  offers	  the	  greatest	  
probability	  of	  complete	  remission	  and	  cure.	  Patients	  who	  opted	  for	  supportive	  care	  
often	  never	  underwent	  cytogenetic	  work-­‐up	  as	  the	  results	  were	  not	  going	  to	  change	  





In	  patients	  receiving	  standard	  induction	  chemotherapy,	  determining	  whether	  a	  
patient	  has	  achieved	  remission	  is	  critical	  for	  treatment	  decisions.	  Three	  patients	  
(27.3%)	  in	  this	  study	  achieved	  complete	  remission	  following	  their	  initial	  course	  of	  
standard	  induction	  chemotherapy.	  This	  is	  slightly	  lower	  than	  similar	  studies	  with	  
complete	  remission	  rate	  of	  42%	  to	  52%	  (44,73).	  In	  this	  study,	  two	  additional	  
patients	  achieved	  complete	  remission	  on	  other	  agents	  after	  being	  refractory	  to	  
standard	  induction	  chemotherapy.	  This	  brought	  the	  total	  remission	  rate	  to	  45.5%.	  
None	  of	  the	  patients	  receiving	  decitabine	  therapy	  had	  a	  confirmed	  complete	  
remission.	  In	  this	  group	  of	  older	  patients,	  achieving	  remission	  most	  likely	  would	  not	  
have	  changed	  clinical	  decision-­‐making	  and	  therefore	  the	  patients	  were	  spared	  
unnecessary	  bone	  marrow	  biopsies.	  Other	  decitabine	  studies	  have	  demonstrated	  
complete	  remission	  rates	  ranging	  from	  15.7%	  to	  28%	  (70,72,73).	  Current	  research	  
is	  exploring	  using	  decitabine	  to	  achieve	  complete	  remission	  with	  the	  goal	  of	  
proceeding	  to	  bone	  marrow	  stem	  cell	  transplant.	  Patients	  in	  this	  study	  received	  a	  




Median	  overall	  survival	  in	  the	  standard	  induction	  chemotherapy	  group	  was	  7	  
months,	  within	  a	  range	  of	  6.7	  to	  12.8	  months	  seen	  in	  other	  studies	  (44,73).	  
Decitabine	  patients	  had	  median	  survival	  of	  9	  months,	  compared	  with	  a	  range	  of	  7.7	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to	  8.8	  months	  seen	  in	  other	  studies	  (70,72,73).	  Patients	  in	  this	  study	  receiving	  
supportive	  care	  only	  had	  a	  poor	  median	  survival	  of	  0.6	  months,	  considerably	  less	  
than	  the	  range	  of	  1.7	  to	  5	  months	  seen	  in	  other	  studies	  (48,72).	  This	  study	  
demonstrated	  a	  nonsignificant	  but	  positive	  trend	  for	  increased	  survival	  in	  older	  
patients	  receiving	  decitabine	  therapy	  when	  compared	  to	  standard	  induction	  
chemotherapy.	  This	  finding	  is	  consistent	  with	  other	  papers	  demonstrating	  
decitabine	  to	  be	  superior	  or	  not	  inferior	  in	  this	  older	  and	  difficult	  to	  treat	  patient	  
group	  (70,72,73).	  	  
	  
Achieving	  remission	  has	  long	  been	  the	  goal	  in	  AML	  patients,	  as	  remission	  was	  
believed	  to	  lead	  to	  increased	  survival	  and	  improved	  quality	  of	  life	  (4).	  Yet	  this	  study	  
and	  others	  demonstrate	  that	  increased	  survival	  is	  not	  contingent	  on	  achieving	  
remission	  or	  even	  assessing	  whether	  remission	  has	  been	  achieved.	  Instead,	  other	  
forms	  of	  leukemic	  response,	  such	  as	  to	  the	  hypomethylating	  agent	  decitabine,	  can	  be	  
effective	  in	  reducing	  mortality	  in	  older	  patients	  with	  AML	  (44,70,72,73).	  
	  
Quality	  of	  life	  
While	  overall	  survival	  had	  been	  assessed	  in	  prior	  studies	  comparing	  decitabine	  to	  
other	  chemotherapeutic	  agents,	  quality	  of	  life	  has	  not	  been	  studied.	  Given	  the	  
retrospective	  nature	  of	  this	  study,	  it	  was	  not	  possible	  to	  measure	  quality	  of	  life	  using	  
traditional	  questionnaires	  (75).	  	  As	  a	  surrogate	  for	  quality	  of	  life,	  the	  number	  of	  days	  
spent	  in	  the	  hospital	  and	  the	  number	  of	  outpatient	  visits	  were	  examined.	  While	  not	  
a	  comprehensive	  assessment,	  this	  data	  does	  offer	  some	  insights	  into	  of	  quality	  of	  life	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and	  was	  possible	  to	  gather	  posthumously.	  Patients	  receiving	  decitabine	  spent	  
significantly	  fewer	  days	  in	  the	  hospital	  (30	  versus	  41	  days)	  and	  a	  significantly	  
smaller	  proportion	  of	  their	  lives	  (8.8%	  versus	  33.1%)	  from	  diagnosis	  to	  death	  in	  the	  
hospital.	  However,	  this	  does	  not	  mean	  the	  decitabine	  patients	  received	  less	  medical	  
care.	  Instead,	  their	  care	  was	  shifted	  to	  the	  outpatient	  setting	  where	  they	  had	  
significantly	  more	  visits	  (12	  versus	  1	  visits)	  than	  those	  receiving	  standard	  induction	  
chemotherapy.	  	  
	  
Given	  the	  retrospective	  nature	  of	  this	  study	  and	  the	  variability	  in	  accessible	  medical	  
records,	  it	  was	  not	  possible	  to	  give	  a	  full	  account	  of	  treatment	  related	  adverse	  
events.	  Instead,	  early	  death,	  defined	  as	  mortality	  within	  30	  days	  of	  initiation	  of	  
chemotherapy,	  is	  a	  standard	  for	  assessing	  chemotherapy	  toxicity	  (4,76).	  The	  early	  
death	  rates	  for	  both	  standard	  induction	  chemotherapy	  and	  decitabine	  therapy	  were	  
low,	  18.2%	  and	  9.1%,	  respectively.	  These	  numbers	  compare	  well	  to	  the	  Swedish	  
Acute	  Leukemia	  Registry	  of	  more	  than	  800	  patients	  over	  age	  65	  receiving	  intensive	  
chemotherapy	  in	  which	  13.3%	  of	  patients	  experienced	  early	  death	  (4).	  A	  large	  
number	  of	  early	  deaths	  were	  seen	  in	  the	  supportive	  care	  only	  group	  where	  57.1%	  of	  
patients	  died	  within	  30	  days.	  This	  is	  not	  surprising	  as	  the	  supportive	  care	  group	  was	  
significantly	  older	  and	  likely	  had	  a	  very	  poor	  performance	  status	  that	  made	  them	  
unfit	  to	  attempt	  therapy.	  The	  57.1%	  in	  this	  study	  was	  greater	  than	  the	  39%	  of	  
nearly	  1000	  patients	  in	  the	  Swedish	  Acute	  Leukemia	  Registry	  receiving	  supportive	  




This	  study	  was	  limited	  in	  several	  ways.	  As	  a	  retrospective	  chart	  review,	  there	  was	  
no	  randomization.	  Initial	  characteristics	  of	  the	  three	  patient	  groups	  were	  not	  
matched,	  most	  importantly	  in	  terms	  of	  age.	  Some	  data,	  such	  as	  treatment-­‐related	  
adverse	  events	  and	  initial	  cytogenetics,	  was	  not	  accessible	  for	  all	  patients.	  Patients	  
undergoing	  decitabine	  therapy	  did	  not	  have	  bone	  marrow	  biopsies,	  making	  it	  
impossible	  to	  determine	  if	  they	  had	  achieved	  remission.	  The	  number	  of	  patients	  in	  
this	  single-­‐institution	  study	  was	  small,	  limiting	  the	  ability	  to	  achieve	  statistical	  
significance	  in	  survival	  differences.	  	  	  
	  
In	  conclusion,	  this	  retrospective	  study	  of	  first-­‐line	  treatment	  of	  older	  patients	  with	  
AML	  found	  fewer	  inpatient	  days	  and	  a	  positive	  trend	  for	  increased	  survival	  in	  
patients	  receiving	  decitabine	  therapy	  compared	  to	  patients	  receiving	  standard	  
induction	  chemotherapy.	  It	  is	  important	  to	  note	  that	  the	  decitabine	  group	  did	  better	  
despite	  the	  fact	  that	  it	  was	  significantly	  older	  than	  the	  standard	  induction	  
chemotherapy	  group	  and	  would	  therefore	  be	  expected	  to	  do	  worse.	  This	  study	  is	  
novel	  in	  its	  inclusion	  of	  inpatient	  days	  as	  another	  metric	  by	  which	  decitabine	  is	  
superior	  to	  standard	  induction	  chemotherapy.	  	  
	  
It	  would	  potentially	  be	  helpful	  and	  empowering	  for	  patient	  decision-­‐making	  if	  
differences	  in	  quality	  of	  life	  for	  AML	  treatment	  regimens	  were	  made	  known.	  
Patients	  who	  receive	  decitabine	  therapy	  can	  expect	  to	  require	  less	  hospital	  care	  but	  
more	  outpatient	  visits	  in	  comparison	  to	  those	  receiving	  standard	  induction	  
chemotherapy.	  Given	  the	  limited	  life	  expectancy	  and	  very	  high	  one-­‐year	  mortality	  in	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AML,	  providing	  patients	  with	  the	  most	  information	  possible	  regarding	  the	  options	  
for	  how	  they	  spend	  their	  time	  would	  be	  beneficial.	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Figure	  1.	  Participant	  flow	  diagram.	  
Demonstrates	  inclusion	  and	  exclusion	  criteria	  for	  276	  patients	  assessed	  for	  
eligibility	  in	  this	  study.	  The	  three	  groups	  ultimately	  chosen	  for	  this	  study	  included	  
11	  patients	  receiving	  first-­‐line	  decitabine,	  14	  patients	  receiving	  supportive	  care	  
only,	  and	  11	  patients	  receiving	  first-­‐line	  idarubicin	  +	  cytarabine	  standard	  induction	  
chemotherapy.	  	  
	  







Table	  1.	  Patient	  demographics	  and	  baseline	  clinical	  characteristics.	  	  
There	  exist	  statistically	  significant	  differences	  in	  age	  between	  standard	  induction	  
chemotherapy	  and	  decitabine	  groups	  (P	  =	  .020)	  and	  between	  decitabine	  and	  
supportive	  care	  groups	  (P	  =	  .0005).	  There	  were	  no	  statistically	  significant	  
differences	  in	  sex,	  white	  blood	  cells,	  hemoglobin,	  platelets,	  or	  cytogenetics.	  
	  





Table	  2.	  Treatment	  Response.	  
Select	  demographics,	  baseline	  characteristics,	  and	  treatment	  response	  for	  each	  
patient	  in	  this	  study.	  Median	  values	  and	  standard	  deviations	  are	  presented	  for	  age,	  
survival,	  inpatient	  days,	  percentage	  of	  life	  from	  diagnosis	  to	  death	  spent	  in	  the	  
hospital,	  and	  outpatient	  days.	  P-­‐values	  compare	  the	  standard	  induction	  
chemotherapy	  and	  decitabine	  groups;	  the	  supportive	  care	  group	  was	  not	  included	  in	  
the	  above	  P-­‐value	  calculations.	  Statistically	  significant	  differences	  were	  observed	  in	  
patient	  age,	  number	  of	  days	  spent	  in	  the	  hospital,	  percentage	  of	  time	  spent	  in	  the	  






Figure	  2.	  Overall	  Survival.	  
Kaplan-­‐Meier	  curve	  of	  overall	  survival	  in	  the	  three	  treatment	  groups.	  There	  was	  no	  
statistically	  significant	  difference	  in	  overall	  survival	  between	  the	  standard	  induction	  
chemotherapy	  and	  decitabine	  groups	  but	  the	  supportive	  care	  only	  group	  had	  







Figure	  3.	  Inpatient	  and	  Outpatient	  Days.	  
Mean	  number	  of	  days	  spent	  in	  the	  hospital	  as	  an	  inpatient	  and	  mean	  number	  of	  
outpatient	  visits.	  Error	  bars	  demonstrate	  95%	  confidence	  interval.	  There	  were	  
statistically	  significant	  differences	  (*	  P	  <	  .05)	  between	  the	  standard	  induction	  
chemotherapy	  and	  decitabine	  groups	  in	  both	  inpatient	  and	  outpatient	  days.	  
Statistical	  significance	  was	  not	  calculated	  for	  the	  supportive	  care	  group.	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